| Literature DB >> 31583036 |
Seema Zargar1, Mona Alonazi1, Humaira Rizwana2, Tanveer A Wani3.
Abstract
BACKGROUND: Thioacetamide (TAA), a class 2B-type carcinogen, is a potent toxicant. Toxicities caused by this compound in various tissues due to oxidative stress, increase of proinflammatory markers, and apoptosis have been reported; however, reports on kidney toxicity are negligible. Resveratrol (RSV), on the other hand, has demonstrated antioxidant and anti-inflammatory effects in different cases. Resveratrol's protective effects against TAA kidney toxicity were investigated in four rat groups.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31583036 PMCID: PMC6754927 DOI: 10.1155/2019/1702959
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Effect of thioacetamide and resveratrol on the IL-4. IL-4 concentrations are expressed as pg/mg protein (n = 8) for the treated groups compared to the control group. ∗∗∗∗P < 0.0001; ns: nonsignificant.
Figure 2Effect of thioacetamide and resveratrol on TNF-α. TNF-α concentrations are expressed as pg/mg protein (n = 8) for the treated groups compared to the control group. ∗∗∗∗P < 0.0001; ns: nonsignificant.
Figure 3Effect of thioacetamide and resveratrol on IFN-γ. IFN-γ concentrations are expressed as pg/mg protein (n = 8) when treated groups are compared to the control group. ∗∗∗∗P < 0.0001; ∗∗P < 0.01; ns: nonsignificant.
Figure 4Effect of thioacetamide and resveratrol on 8-OHdG. 8-OHdG concentrations (n = 8) are expressed as ng/100 mg tissue when treated groups are compared to control group. ∗∗∗∗P < 0.0001; ns: nonsignificant.
Effect of thioacetamide-induced changes alone and combined with resveratrol on the levels of kidney function and oxidative stress markers. Data are represented as mean ± SD of three independently performed experiments; each group had 8 rats for all experiments conducted: TAA-treated, 0.3% for two weeks; RSV-treated, 10 mg/kg bw for 2 weeks; and TAA+RSV-treated, 0.3%+10 mg/kg bw simultaneously for 2 weeks.
| Parameters | Control | TAA-treated | RSV-treated | TAA+RSV-treated |
|---|---|---|---|---|
| BUN (mg/mg protein) | 18.31 ± 2.9b | 44.03 ± 1.9acd | 20.7 ± 1.6b | 17.88 ± 2.0b |
| Creatinine (mg/mg protein) | 0.31 ± 0.06bcd | 0.58 ± 0.03ac | 0.44 ± 0.02bd | 0.37 ± 0.03bc |
| Creatine kinase (U/mg protein) | 57.71 ± 2.6b | 67.66 ± 1.6ac | 58.26 ± 1.8b | 60.28 ± 5.9b |
| Lipid peroxidation (mmoles/mg protein) | 2.20 ± 0.537bc | 4.24 ± 0.57acd | 1.81 ± 0.71abd | 2.38 ± 0.12b |
| Catalase (U/mg protein) | 1.08 ± 0.46bd | 0.33 ± 0.06ad | 0.98 ± 0.22b | 1.33 ± 0.23b |
aSignificant (P < 0.05) compared to control; bsignificant (P < 0.05) compared to TAA-treated group; csignificant (P < 0.05) compared to with the RSV-treated group; dsignificant (P < 0.05) compared to simultaneous treatment of TAA+RSV-treated group.
Figure 5HE staining of thioacetamide and resveratrol treatments in kidney tissue sections at 40x. (a) Control group: having normal glomerulus and kidney tubules. (b) TAA-treated group: TAA treatment led to distortion of the glomerulus with apoptotic cells. (c) RSV-treated group: having normal glomerulus and tubules. (d) RSV+TAA-treated group: treatment with RSV before TAA preserved glomerular congestion while congestion of tubules and apoptotic cells were completely treated.